文献速递消化内镜消化道肿瘤与早癌食管胃疾病与幽门螺杆菌

非内镜胶囊海绵分诊试验用于反流症状:英国国家医疗服务体系前瞻性真实世界评估结果

Use of a Non-Endoscopic Capsule-Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real-World Evaluation.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-10

这项英国国家医疗服务体系多中心前瞻性真实世界队列研究纳入2021年2月至2022年8月间在內镜等待名单上的反流症状患者,比较接受胶囊海绵分诊试验者与标准内镜路径的合格患者。胶囊海绵分诊可行、安全且可接受,大幅减少常规反流转诊的内镜负担,对巴雷特食管的诊断产出良好。

要点

  • 详细亚组分析中1411/1549(92%)成功吞服胶囊,其中307/1411(21.8%)需内镜。
  • 胶囊海绵生物标志物阳性且行内镜者19.8%检出巴雷特食管,阴性者因持续症状转诊内镜者无一检出(p=0.0002)。

核心结论

  • 胶囊海绵分诊可行、安全且可接受,大幅减少常规反流转诊的内镜负担,对巴雷特食管的诊断产出良好,更长期随访将有助于评估该项目的影响及胶囊海绵在诊断路径中的位置。

研究设计与样本

  • 英国国家医疗服务体系多中心前瞻性真实世界队列研究,纳入2021年2月至2022年8月间在內镜等待名单上、被提供胶囊海绵分诊的反流症状患者(试验组),与标准内镜路径的合格患者(反事实组)比较。

主要发现

  • 详细亚组分析中1411/1549(92%)到检并成功吞服胶囊,其中307/1411(21.8%)需要内镜。
  • 胶囊海绵生物标志物阳性且行内镜的111例患者中,19.8%检出巴雷特食管;因持续症状转诊内镜的胶囊海绵生物标志物阴性患者中无一检出巴雷特食管(p=0.0002)。
  • 接受调查者中267/357(82%)对替代路径表示满意。

关键数值与推荐

  • 胶囊海绵生物标志物阳性且行内镜者巴雷特食管检出率为19.8%,阴性者因持续症状转诊内镜者检出率为0%(p=0.0002)。

临床怎么用

  • 原文结论指出胶囊海绵分诊可行、安全且可接受,大幅减少常规反流转诊的内镜负担,对巴雷特食管的诊断产出良好。

局限性

  • 原文指出更长期随访将有助于有把握地评估该项目的影响及胶囊海绵在诊断路径中的位置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acid reflux is a common presentation in primary care leading to a high volume of referrals to endoscopy that are often normal. AIMS: To determine whether a non-endoscopic capsule sponge biomarker test could triage patients with low-risk reflux symptoms, reduce endoscopy waiting lists and identify Barrett's oesophagus in a real-world setting. METHODS: Patients with reflux symptoms on NHS endoscopy waiting lists who were offered a capsule sponge (test group) between February 2021 and August 2022 were included in this national multicentre prospective cohort study and compared with eligible patients on the standard endoscopy pathway (counterfactual group). RESULTS: Two thousand one hundred seventy patients from 23 hospitals undertook a capsule sponge triage test and submitted follow-up data, of whom 1694 (78%) were discharged without endoscopy and 476 (22%) were referred for endoscopy. In a detailed subgroup analysis 1411/1549 (92%) attended and successfully swallowed the capsule of whom 307/1411 (21.8%) required endoscopy. Of 111 patients with positive capsule sponge biomarker results who had endoscopy, 19.8% had Barrett's oesophagus. In comparison, in patients with negative sponge biomarkers who were referred for endoscopy due to ongoing symptoms, none had Barrett's oesophagus (p = 0.0002). Eighty-two percent surveyed (267/357) were satisfied with the alternative pathway. CONCLUSIONS: Capsule sponge triage is feasible, safe and acceptable. It substantially reduces the endoscopy burden for routine reflux referrals with a favourable diagnostic yield for Barrett's oesophagus. Longer term follow-up will help to confidently assess the impact of the programme and place of capsule sponge in the diagnostic pathway.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gourgiotis V, Graham C, Foerster K, et al. Use of a Non-Endoscopic Capsule-Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real-World Evaluation. Aliment Pharmacol Ther. 2025. PMID: 39794909. doi:10.1111/apt.18472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。